Generics Bulletin is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Interview: Galapagos Pipeline In Good Shape

Following more promising rheumatoid arthritis data on filgotinib at EULAR, the Belgian biotech's chief medical officer Walid Abi-Saab tells Scrip about the JAK inhibitor's promise in a number of other indications.

Immune Disorders Clinical Trials

Keeping Track: Approvals For Polivy, Keytruda, FDA Applause For Biosimilars

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Drug Pricing Policy Show Moves Into Next Act With Biopharmas' Suit Against DTC Ad Rule

Merck, Lilly, Amgen join advertisers in suit against HHS; rule helped Trump administration spotlight industry pricing practices but potential impact has always been unclear.

Pricing Debate Legal Issues

FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar

Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.

Biosimilars United States
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register